Results 41 to 50 of about 126,909 (281)

Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy [PDF]

, 2003
It is generally believed that increase in adult contractile cardiac mass can be accomplished only by hypertrophy of existing myocytes. Documentation of myocardial regeneration in acute stress has challenged this dogma and led to the proposition that ...
Anversa P., CASTALDO, CLOTILDE, Kajstura J, Leri A, Nadal Ginard B, Quaini E, Quaini F, Tasca G, Torella D, Urbanek K   +9 more
core   +1 more source

Micro-RNAs of the miR-15 family modulate cardiomyocyte survival and cardiac repair [PDF]

, 2015
A family of microRNAs, called the miR-15 family, which includes miR-195, are shown to be up-regulated during pathological cardiac remodeling and repress the expression of mRNAs required for cell proliferation and survival, with consequent loss of ...
Olson, Eric N., van Rooij, Eva
core   +1 more source

Cardiac myosin inhibitor, mavacamten, improves myocardial relaxation in mouse HFpEF model

Cardiovascular Research, 2022
Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Medical Research Council (NMRC) Background / Introduction There are currently no treatments for ...
YH Lin, EP Yap, G Sivakumar, NGZ Tee, CJA Ramachondra, DJ Hausenloy   +5 more
openaire   +1 more source

Differentiation of spontaneously contracting cardiomyocytes from non-virally reprogrammed human amniotic fluid stem cells. [PDF]

PLoS ONE, 2017
Congenital heart defects are the most common birth defect. The limiting factor in tissue engineering repair strategies is an autologous source of functional cardiomyocytes.
Aaron J Velasquez-Mao, Christopher J M Tsao, Madeline N Monroe, Xavier Legras, Beatrice Bissig-Choisat, Karl-Dimiter Bissig, Rodrigo Ruano, Jeffrey G Jacot   +7 more
doaj   +1 more source

Micro-RNAS that control myosin expression and myofiber identity [PDF]

, 2015
The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and/or miR-208b can be used to repress fast fiber genes and activate slow fiber
Olson, Eric N., van Rooij, Eva
core   +1 more source

Cardiac myosin inhibitors in hypertrophic cardiomyopathy: gaps in knowledge and future opportunities

Shanghai Chest
Mehran Rahimi, Monica Ahluwalia, Ralf Martz Sulague, Jacques Kpodonu   +3 more
semanticscholar   +2 more sources

Genetically Encoded Biosensors Reveal PKA Hyperphosphorylation on the Myofilaments in Rabbit Heart Failure [PDF]

, 2016
RATIONALE: In heart failure, myofilament proteins display abnormal phosphorylation, which contributes to contractile dysfunction. The mechanisms underlying the dysregulation of protein phosphorylation on myofilaments is not clear.
Barbagallo, Federica, Bers, Donald, Bossuyt, Julie, Ferrier, William, Fu, Qin, Ginsburg, Kenneth S., Isidori, Andrea, Li, Minghui, Naro, Fabio, Patel, Hemal H., Reddy, Gopireddy R., Shi, Qian, Wang, Qingtong, West, Toni, Xiang, Yang K., Xu, Bing   +15 more
core   +1 more source

Left Ventricular Hypertrophy and Hypertrophic Cardiomyopathy in Adult Solid Organ Transplant Recipients

Transplantation Direct, 2022
Background. Hypertrophic cardiomyopathy (HCM) in pediatric solid organ transplant recipients has been reported in association with use of calcineurin inhibitors.
Nosheen Reza, MD, Alejandro De Feria, MD, Teresa Wang, MD, Jessica L. Chowns, CGC, Lily Hoffman-Andrews, CGC, Jessica Kim, BS, Nicole Hornsby, CRNP, Amy Marzolf, CRNP, Pavan Atluri, MD, Howard C. Herrmann, MD, Anjali Tiku Owens, MD   +10 more
doaj   +1 more source

Micro-RNA family that modulates fibrosis and uses thereof [PDF]

, 2017
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response
Olson, Eric N., van Rooij, Eva
core   +1 more source

Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?

Current Heart Failure Reports, 2023
Purpose of Review Cardiac myosin inhibitors (CMIs) and activators are emerging therapies for hypertrophic cardiomyopathy (HCM) and heart failure with reduced ejection fraction (HFrEF), respectively.
M. Lee, A. Masri
semanticscholar   +1 more source